Pfizer/BioNTech COVID-19 vaccine highly protective in 12-18 age group - U.S. CDC study

The Pfizer Inc/BioNTech SE COVID-19 vaccine was 93% effective in preventing hospitalizations among those aged 12 to 18, according to an analysis released by the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday. The study was conducted between June and September, when the extremely contagious Delta variant of the coronavirus was predominant. Yet, the data from 19 pediatric hospitals showed that among the 179 patients who were hospitalized for COVID-19, 97% were unvaccinated, providing reassurance of the vaccine's efficacy.